To PEGylate or Not To PEGylate Therapeutics?
- PMID: 31100258
- DOI: 10.1016/j.chembiol.2019.04.014
To PEGylate or Not To PEGylate Therapeutics?
Abstract
PEGylation is a common modulator of pharmacokinetics for therapeutic agents in vivo. In this issue of Cell Chemical Biology, Moreno et al. (2019) show anti-PEG antibodies may directly inhibit the activity of a PEGylated aptamer, RB006, both in vitro and in vivo, and the issues surrounding anti-PEG antibodies are discussed.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment on
-
Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers.Cell Chem Biol. 2019 May 16;26(5):634-644.e3. doi: 10.1016/j.chembiol.2019.02.001. Epub 2019 Feb 28. Cell Chem Biol. 2019. PMID: 30827937 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
